Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00588731 · ClinicalTrials.gov registry record · Phase 2
Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia
A Phase 2 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT00588731 is a Phase 2 study that has completed, run by Yale University. The registered enrollment target is 41 participants.
The verdict
NCT00588731, a Phase 2 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
This study is a six-week, randomized, placebo-controlled, fixed dose trial comparing cannabidiol Vs. placebo added to a stable dose of antipsychotic medications in patients diagnosed with schizophrenia.
Interventions
- DRUG Placebo
- DRUG Cannabidiol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2009-02 |
| Est. Completion | 2013-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00588731
The ClinicalTrials.gov registry entry for NCT00588731 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00588731 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00588731 about?
NCT00588731 is a clinical study titled "Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia". This study is a six-week, randomized, placebo-controlled, fixed dose trial comparing cannabidiol Vs. placebo added to a stable dose of antipsychotic medications in patients diagnosed with schizophrenia.
What is the current status of trial NCT00588731?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2009-02. Estimated completion is 2013-12.
What interventions are being tested in trial NCT00588731?
The interventions under investigation include: Placebo (DRUG), Cannabidiol (DRUG).
Who is sponsoring clinical trial NCT00588731?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.